Dinner S, Dunn TJ, Price E, et al. A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide, weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma. Int J Hematol. 2018, 108(3):267-273. doi: 10.1007/s12185-018-2468-5.
Advertisement
Articles by Dinner S, Dunn TJ, Price E, et al. A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide, weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma. Int J Hematol. 2018, 108(3):267-273. doi: 10.1007/s12185-018-2468-5.
Advertisement
Latest Updated Articles
- Study Summary: Amrubicin, Lenalidomide, and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Published: October 24th 2018 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Contributor: Engagement Is the Missing Link in Kidney Care—How Payers and Value-Based Partnerships Can Close the Gap
2
Different Communication of HIV Risk Affects PrEP Interest
3
FDA Approves Pembrolizumab Plus Enfortumab Vedotin for MIBC
4
BPA Exposure Linked to 127 Million Global Metabolic Disease Cases
5
